Emergent BioSolutions(EBS) - 2023 Q4 - Earnings Call Presentation

--- Total Segment Adjusted Gross Margin %2 1.All financial information incorporated within this presentation is unaudited. 2. See "End Notes: Non-GAAP Financial Measures" and "Appendix" for the definitions of non-GAAP terms and reconciliations to the most directly comparable GAAP financial measures. 15 FINANCIALS Key Financial Performance Metrics FY 2023 vs. FY 2022 (Continued)1 (in millions) FY 2022 FY 2023 SG&A --- $188.3$96.8 $339.5$368.4 30% 35% Cost of Commercial Product Sales Cost of MCM Product ...